Metalloprotease inhibitors as anti-inflammatory agents: An evolving target?

Current Opinion in Investigational Drugs

Volumn 5, Issue 5, 2004, Pages 511-516

  Whelan, Clifford J ^a  

^a Phlogopharm Ltd   (United Kingdom)

Author keywords

Arthritis; COPD; Inflammatory bowel disease; Ischemic heart disease; Metalloprotease inhibitor; Tissue remodeling

Indexed keywords

ANTIINFLAMMATORY AGENT; ENZYME INHIBITOR; METALLOPROTEINASE;

ANIMAL; ARTERIOSCLEROSIS; ARTHRITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ANTAGONISM; ENTERITIS; ENZYMOLOGY; HUMAN; METABOLISM; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIOSCLEROSIS; ARTHRITIS; ENZYME INHIBITORS; HUMANS; INFLAMMATORY BOWEL DISEASES; METALLOPROTEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 3343006385     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Borkakoti N: Structural characteristics of the matrix metalloproteases. In: Metalloproteases as Targets for Anti-inflammatory Drugs. Bottomley KMK, Bradshaw D, Nixon JS (Eds), Birkhauser, Basel, Switzerland (1999):1-16.
2. Cawston TE: Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther (1996) 70(3):163-182.
3. Skotnicki JS, Levin JI, Zask A, Killar LM: Matrix metalloproteinase inhibitors. In: Metalloproteases as Targets for Anti-inflammatory Drugs. Bottomley KMK, Bradshaw D, Nixon JS (Eds), Birkhauser, Basel, Switzerland (1999):17-57.
4. Belvisi MG, Bottomley KM: The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): A therapeutic role for inhibitors of MMPs? Inflamm Res (2003) 53(3):95-100.
5. Badger AM, Lee JC: Advances in antiarthritic therapeutics. Drug Development Today (1997) 2:427-435.
6. Lewis EJ, Bishop J, Bottomley KMK, Bradshaw D, Brewster M, Broadhurst MJ, Brown PA, Budd JM, Elliott L, Greenham AK, Johnson WH et al: Ro 32-3555, an orally active collagenase inhibitor prevents cartilage breakdown in vivo and in vitro. Br J Pharmacol (1997) 121(3):540-546.
7. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs (1997) 15(1):61-75.
8. Chubinskaya S, Kuettner KE, Cole AA: Expression of matrix metalloproteinases in normal and damaged articular cartilage from human knee and ankle joints. Lab Invest (1999) 79(12):1669-1677.
9. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K: Contribution of matrilysin (MMP-7) to the metastatic potential of human colorectal cancers. Gut (1999) 45(2):252-258.
10. Curran S, Murray GI: Matrix metalloproteinases in tumour invasion and metastasis. J Pathol (1999) 189(3):300-308.
11. Dennis LJ, Verweij J: Matrix metalloproteinase inhibitors: Present achievements and future prospects. Invest New Drugs (1997) 15(3):175-185.
12. Becker AE, de Boer OJ, van der Wal AC: The role of inflammation and infection in coronary artery disease. Annu Rev Med (2001) 52:289-297.
13. Li YY, Feldman AM: Matrix metalloproteinases in the progression of heart failure: Potential therapeutic implications. Drugs (2001) 61(9):1239-1252.
14. Wahl LM, Shankavaram U, Zhang Y: Role of macrophages in vascular tissue remodelling. Transplant Immunol (1997) 5(3):173-176.
15. Barnes PJ: Mechanisms in COPD: Differences from asthma. Chest (2000) 117(2):10S-14S.
16. Raulo SM, Sorsa T, Tervahartiala T, Pirila E, Maisi P: MMP-9 as a marker of inflammation in tracheal epithelial lining fluid (TELF) and in bronchoalveolar lavage fluid (BALF) of COPD horses. Equine Vet J (2001) 33(2):128-136.
17. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M: Upregulation of gelatinases A and B, collagenases 1 and 2 and increased parenchymal cell death in COPD. Chest (2000) 117(3):684-694.
18. Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, O'Connor CM: Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med (1997) 156(1):240-247.
19. Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs (2000) 59(5):1043-1055.
20. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature (1996) 383(6603):787-793.
21. Romagnani S: Biology of human Th1 and Th2 cells. J Clin Immunol (1995) 15(3):121-129.
22. Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol (2000) 18:217-242.
23. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N et al: A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature (1997) 385(6618):729-733.
24. Parums DV (Ed): Essential Clinical Pathology. Blackwell Science, Oxford, UK (1996).
25. Close DR: Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis (2001) 60(Suppl 3):iii62-iii67.
26. Parnham MJ: Inflammation, mechanisms and therapeutics. Drug News Perspect (1994) 7:567-573.
27. Lee SJ, Kavanaugh A: Pharmacological treatment of established rheumatoid arthritis. Best Pract Res Clin Rheumatol (2003) 17(5):811-829.
28. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P: The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med (2002) 165(5):704-707.
29. Viegi G: Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration (2001) 68(1):4-19.
30. Kawabata K, Hagio T, Matsuoka S: The role of neutrophil elastase in acute lung injury. Eur J Pharmacol (2002) 451(1):1-10.
31. Fletcher C, Peto R: The natural history of chronic airflow obstruction. Br Med J (1977) 1(6077):1645-1648.
32. Jeffery PK: Remodelling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med (2001) 164(10 Pt 1):S28-S38.
33. Jackson AD: Airway goblet-cell mucus secretion. Trends Pharmacol Sci (2001) 22(1):39-45.
34. Fahy JV, Schuster A, Ueki I, Boushey HA, Nadel JA: Mucus hypersecretion in bronchiectasis. The role of neutrophil proteases. Am Rev Respir Dis (1992) 146(6):1430-1433.
35. Coggon D, Taylor AN: Coal mining and chronic obstructive pulmonary disease: A review of the evidence. Thorax (1998) 53(5):398- 407.
36. Ulvestad B, Bakke B, Melbostad E, Fuglerud P, Kongerud J, Lund MB: Increased risk of obstructive pulmonary disease in tunnel workers. Thorax (2000) 55(4):277-282.
37. Lomas DA, Silverman EK: The genetics of chronic obstructive pulmonary disease. Respir Res (2001) 2(1):20-26.
38. Mayer AS, Newman LS: Genetic and environmental modulation of chronic obstructive pulmonary disease. Respir Physiol (2001) 128(1):3-11.
39. Libby P: Inflammation in atherosclerosis. Nature (2002) 420(6917):868-874.
40. Huo Y, Ley K: Adhesion molecules and atherogenesis. Acta Physiol Scand (2001) 173(1):35-43.
41. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature (1993) 362(6423):801-809.
42. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Nerem RM: The pathogenesis of atherosclerosis: An overview. Clin Cardiol (1991) 14(2 Suppl 1):I1-16.
43. Scholkens BA, Landgraf W: ACE inhibition and atherogenesis. Can J Physiol Pharmacol (2002) 80(4):354-359.
44. Schnee JM, Hsueh WA: Angiotensin II, adhesion and cardiac fibrosis. Cardiovasc Res (2000) 46(2):264-268.
45. Vaalamo M, Karjalainen-Lindsberg M-L, Puolakkainen P, Kere J, Saarialho-Kere U: Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12) and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol (1998) 152(4):1005-1014.
46. Pender SLF, Tickle SP, Docherty AJP, Howie D, Wathen NC, MacDonald TT: A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol (1997) 158(4):1582-1590.
47. Sykes AP, Bhogal R, Brampton C, Chander C, Whelan C, Parsons ME, Bird K: The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther (1999) 13(11):1535-1542.
48. Hooper NM: Overview of the biological roles of metalloproteases in health and disease. In: Metalloproteases as Targets for Anti-inflammatory Drugs. Bottomley KMK, Bradshaw D, Nixon JS (Eds), Birkhauser, Basel, Switzerland (1999):145-161.
49. Mohammed FF, Smookler DS, Khokha R: Metalloproteinases, inflammation and rheumatoid arthritis. Ann Rheum Dis (2003) 62(Suppl 2):ii43-ii47.
50. MaCnee W, Rahman I: Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med (2001) 7(2):55-62.
51. Barnes PJ: Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax (1999) 54(3):245-252.
52. Baboir BM: Phagocytes and oxidative stress. Am J Med (2000) 109(1):33-44.
53. Rahman I: Oxidative stress, transcription factors and chromatin remodelling in lung inflammation. Biochem Pharmacol (2002) 64(5-6):935-942.
54. Turato G, Zuin R, Saetta M: Pathogenesis and pathology of COPD. Respiration (2001) 68(2):117-128.
55. Moghadasian MH: Experimental atherosclerosis: A historical overview. Life Sci (2002) 70(8):855-865.
56. Tremblay GM, Janelle MF, Bourbonnais Y: Anti-inflammatory activity of neutrophil elastase inhibitors. Curr Opin Invest Drugs (2003) 4(5):556-565.
57. Hutchinson JW, Tierney GM, Parsons SL, Davis TR: Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br (1998) 80(5):907-908.
58. Zucker S, Cao J, Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene (2000) 19(56):6642-6650.
59. Stone M, Fortin PR, Pacheco-Tena C, Inman RD: Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol (2003) 30(10):2112-2122.
60. Seymour RA, Heasman PA: Tetracyclines in the management of periodontal diseases. A review. J Clin Periodontol (1995) 22(1):22-35.
61. Ramamurthy NS, Rifkin BR, Greenwald RA, Xu JW, Liu Y, Turner G, Golub LM, Vernillo AT: Inhibition of matrix metalloproteinase-mediated bone loss in rats: A comparison of 6 chemically modified tetracyclines. J Periodontol (2002) 73(7):726-734.
62. Briest W, Hölzl A, Rassler B, Deten A, Baba HA, Zimmer HG: Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts. Circ Res (2003) 57(2):379-387.
63. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD: Specificity of inhibition of matrix metalloproteinase activity by doxycycline: Relationship to structure of the enzyme. Arthritis Rheum (1999) 42(6):1140- 1146.
64. Sadowski T, Steinmeyer J: Differential effects of nonsteroidal antiinflammatory drugs on the IL-1 altered expression of plasminogen activators and plasminogen activator inhibitor-1 by articular chondrocytes. Inflamm Res (2002) 51(8):427-433.
65. Markham A, Lamb HM: Infliximab: A review of its use in the management of rheumatoid arthritis. Drugs (2000) 59(6):1341-1359.
66. Maini RN, Taylor PC: Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med (2000) 51:207-229.
67. Del Prete G, Maggi E, Romagnani S: Human Th1 and Th2 cells: Functional properties, mechanisms of regulation and role in disease. Lab Invest (1994) 70(3):299-306.
68. Kvien TK, Uhlig T, Kristiansen IS: Criteria for TNF-targeted therapy in rheumatoid arthritis: Estimates of the number of patients currently eligible. Drugs (2001) 61(12):1711-1720.